Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRC 253

Next Previous
Drug Profile

TRC 253

Alternative Names: JNJ 63576253; TRC-253

Latest Information Update: 25 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Pharmaceutica
  • Developer Janssen Pharmaceutica; TRACON Pharmaceuticals
  • Class Antineoplastics; Aza compounds; Ethers; Fluorinated hydrocarbons; Nitriles; Organic sulfur compounds; Picolines; Piperidines; Pyridines; Small molecules; Spiro compounds
  • Mechanism of Action Androgen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 22 Mar 2021 Phase-II clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (PO) (TRACON Pharmaceuticals pipeline, March 2021)
  • 30 Sep 2020 TRC 253 is still in phase I/II trial for Prostate cancer in USA (NCT02987829)
  • 31 Aug 2020 TRACON Pharmaceuticals plans a phase III trial for Prostate cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top